Study says big pharma may be headed for R&D resurgence

US drug companies have increased the number of new clinical trials by more than 50% since 2002, signaling a possible resurgence in R&D productivity, according to a new study by the Tufts Center for the Study of Drug Development (CSDD). The study found that from 2003 to 2005, the rate at which the 10 top-selling US drug companies initiated clinical trials for new drug candidates rose by 52%, following a 21% decline from 1993–1997 to 1998–2002. “This robust improvement could be the start of a break-out from the R&D productivity doldrums that has plagued the major research-based pharmaceutical companies in recent years,” said Tufts CSDD director Kenneth Kaitin. “The real proof will be in the ability of companies to avoid late-stage development terminations and boost overall clinical success rates.” The study also found that: • Of six specific broad therapeutic categories analyzed, oncology/immunologic and CNS had the greatest shares of new drugs entering clinical testing during the 1993–2002 period. • Respiratory, oncology/immunologic and systemic anti-infective drugs had the highest clinical approval success rates for the 1993–2002 period, while gastrointestinal/metabolism, CNS and cardiovascular drugs had the lowest. • Approximately 20% of self-originated new drugs that enter clinical testing received US marketing approval.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions